Our extensive in vitro and in vivo investigations using formal factorial design allowed us to convincingly demonstrate in neuroblastoma pre-clinical models that (a) irinotecan administered on a protracted schedule has remarkable anti-tumour activity; (b) MGMT inhibition enhances the anti-tumour activity of TMZ, confirming MGMT as a relevant pharmacological target. This evidence concerns the gene MGMT and neuroblastoma.